ADMA Biologics to Participate in Raymond James Institutional Investor Conference
February 22 2021 - 8:00AM
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an
end-to-end commercial biopharmaceutical company dedicated to
manufacturing, marketing and developing specialty plasma-derived
biologics, today announced that Adam Grossman, President and Chief
Executive Officer, will participate in a fireside chat at the
Raymond James Institutional Investor Conference on Monday, March 1,
2021, at 10:50 a.m. ET.
A webcast of the event will be available on the Company’s
website
at https://ir.admabiologics.com/events-webcasts and will
be archived for 90 days following the event.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial biopharmaceutical
company dedicated to manufacturing, marketing and developing
specialty plasma-derived biologics for the treatment of
immunodeficient patients at risk for infection and others at risk
for certain infectious diseases. ADMA currently manufactures and
markets three United States Food and Drug Administration (FDA)
approved plasma-derived biologics for the treatment of immune
deficiencies and the prevention of certain infectious diseases:
ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for
the treatment of primary humoral immunodeficiency (PI); BIVIGAM®
(immune globulin intravenous, human) for the treatment of PI; and
NABI-HB® (hepatitis B immune globulin, human) to provide enhanced
immunity against the hepatitis B virus. ADMA manufactures its
immune globulin products at its FDA-licensed plasma fractionation
and purification facility located in Boca Raton, Florida. Through
its ADMA Bio Centers subsidiary, ADMA also operates as an
FDA-approved source plasma collector in the U.S., which provides a
portion of its blood plasma for the manufacture of its products.
ADMA’s mission is to manufacture, market and develop specialty
plasma-derived, human immune globulins targeted to niche patient
populations for the treatment and prevention of certain infectious
diseases and management of immune compromised patient populations
who suffer from an underlying immune deficiency, or who may be
immune compromised for other medical reasons. ADMA has received
U.S. Patents: 9,107,906, 9,714,283, 9,815,886, 9,969,793 and
10,259,865 related to certain aspects of its products and product
candidates. For more information, please visit
www.admabiologics.com.
COMPANY CONTACT:
Skyler Bloom Director, Investor Relations and Corporate Strategy
| 201-478-5552 | sbloom@admabio.com
INVESTOR RELATIONS CONTACT:
Sam Martin Managing Director, Argot Partners | 212-600-1902 |
sam@argotpartners.com
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Apr 2023 to Apr 2024